Stockscreener 앱 받기
160.07
12.34%
-22.53
시간 외 거래:
155.00
-5.075
-3.17%
전일 마감가:
$182.60
열려 있는:
$140
하루 거래량:
756.75K
Relative Volume:
1.82
시가총액:
$90.13M
수익:
$7.10M
순이익/손실:
$-39.43M
주가수익비율:
-170.29
EPS:
-0.94
순현금흐름:
$-46.50M
1주 성능:
+1,699%
1개월 성능:
-70.54%
6개월 성능:
-86.69%
1년 성능:
-90.34%
1일 변동 폭
$138.01
$175.00
1주일 범위
$7.88
$240.00
52주 변동 폭
$7.26
$543.38
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
SPRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
160.07 | 102.81M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-03-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 개시 | Guggenheim | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
Spruce Biosciences (SPRB) Secures $50M for Therapy Advancements - GuruFocus
Medical Stocks To ConsiderOctober 6th - MarketBeat
Spruce Biosciences (SPRB) Secures $50M for Enzyme Replacement Therapy - GuruFocus
Spruce Biosciences (SPRB) Secures $50 Million for Enzyme Therapy Development - GuruFocus
Spruce Biosciences secures $50 million in private placement - Investing.com
Spruce Biosciences (SPRB) Secures $50M in Private Placement for Therapy Advancement - GuruFocus
Spruce Biosciences announces $50.0 million private placement financing - MarketScreener
Spruce Biosciences Announces $50.0 Million Private Placement Financing - Business Wire
Small Cap Stocks To Follow Today – October 6th - Defense World
Three Biotech Stocks Jump After Big Regulatory Wins - Finimize
Spruce Biosciences Stock: Emergent Surges and Market Implications - timothysykes.com
Spruce Biosciences’ Breakthrough: Stock Skyrockets - StocksToTrade
Spruce Biosciences Soars: What’s Driving the Surge? - timothysykes.com
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
SPRB Stock Hits 19-Month High Amid Trading Halts - Stocktwits
Spruce Biosciences Stock Surges: Analyzing Breakthrough - StocksToTrade
Spruce Biosciences (SPRB) Stock: Rare Disease Breakthrough Sends Shares Soaring Over 1,300% - parameter.io
This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barron's
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech
Spruce Biosciences (SPRB) Stock Soars 1,378% on FDA Breakthrough Status - MoneyCheck
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings - RTTNews
Spruce Biosciences Almost Doubles Premarket as FDA Grants Breakthrough Therapy Designation for Tralesinidase Alfa in Sanfilippo Syndrome - MarketScreener
Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside - Stocktwits
Why Is Spruce Biosciences Stock (SPRB) Surging Today? - TipRanks
Spruce Biosciences (SPRB) Stock Jumps 30% After Hours Following Red Hot Rally On Monday: Here's Why - Benzinga
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Spruce Biosciences Stock Resumes Trading: What to Expect? - timothysykes.com
Why This Biotech Stock Just Rocketed Almost 1,400% - Investor's Business Daily
Spruce Biosciences Surges on FDA Breakthrough: Is SPRB’s Rally Sustainable? - Azat TV
Why Spruce Biosciences Just Skyrocketed More Than 1,600% - inkl
SPRB’s Stock Market Moves: Key Insights - StocksToTrade
Spruce Biosciences (SPRB) Surges 1,244% on FDA Breakthrough Ther - GuruFocus
FDA Grants Breakthrough Therapy Status to Spruce Biosciences’ TA-ERT for MPS IIIB - el-balad.com
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy - Seeking Alpha
Promising Pharmaceutical Stocks Worth WatchingOctober 6th - MarketBeat
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade? - ts2.tech
SPRB’s Wild Ride: Understanding Today’s Market Move - timothysykes.com
Spruce Biosciences’ Blockchain Breakthrough - StocksToTrade
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge - Benzinga
Spruce Biosciences shares pop after FDA grants Breakthrough Therapy Designation for rare disease treatment - Proactive financial news
Spruce Biosciences soars after FDA's 'breakthrough therapy' tag for co's drug - TradingView
Spruce Biosciences Stock Is Soaring Today: Here's Why - Benzinga
Why Did Spruce Biosciences Stock Quadruple Today? - Stocktwits
Spruce Biosciences Rockets Sky-High on FDA Breakthrough for Rare Kids’ Brain Therapy - RagingBull
Spruce Biosciences (SPRB) Gains FDA Breakthrough Designation for Key Therapy - GuruFocus
Spruce Biosciences' TA-ERT Secures FDA's Breakthrough Therapy Designation, Stock Surges - Nasdaq
FDA grants breakthrough therapy designation to Spruce’s MPS IIIB drug By Investing.com - Investing.com Canada
Spruce Biosciences receives U.S. FDA breakthrough therapy designation for Tralesinidase Alfa enzyme replacement therapy in Sanfilippo syndrome type B (MPS IIIB) - MarketScreener
Spruce Biosciences stock soars after receiving FDA Breakthrough Therapy status - Investing.com
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.05%
4.71%
자본화:
|
볼륨(24시간):